Two Cases of Serotonin Syndrome with Venlafaxine and Calcineurin Inhibitors

Psychosomatics

Volumn 52, Issue 3, 2011, Pages 286-290

  Newey, Christopher R ^a   Khawam, Elias ^a   Coffman, Kathy ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; TACROLIMUS; VENLAFAXINE; ANTIDEPRESSANT AGENT; CALCINEURIN; CYCLOHEXANOL DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATAXIA; CASE REPORT; CLONUS; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR DEPRESSION; MYOCLONUS; NEUROIMAGING; NYSTAGMUS; RIGHT LOWER EXTREMITY CLONUS; RIGIDITY; SEROTONIN SYNDROME; SIDE EFFECT; SPASTICITY; TREMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CALCINEURIN; CYCLOHEXANOLS; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SEROTONIN SYNDROME; TACROLIMUS;

EID: 80052908152     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2010.12.007     Document Type: Article

References (32)

1. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
2. Dunkley E.J., Isbister G.K., Sibbritt D., et al. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003, 96:635-642.
3. Pan J.J., Shen W.W. Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother 2003, 37:209-211.
4. Houlihan D.J. Serotonin syndrome resulting from co-administration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 2004, 38:411-413.
5. Fisher A.A., Davis M.W. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002, 36:67-71.
6. Lang P.O., Hasso Y., Hilleret H., et al. Serotonin syndrome as a result of escitalopram and cyclosporin combination in an 84-year-old woman. Rev Med Interne 2008, 29:583-586.
7. Wong E.H., Chan N.N., Sze K.H., et al. Serotonin syndrome in a renal transplant patient. J R Soc Med 2002, 95:304-305.
8. Beauchesne P.R., Chung N.S., Wasan K.M. Cyclosporine A: A review of current oral and intravenous delivery systems. Drug Dev Ind Pharm 2007, 33:211-220.
9. Testa G., Klintmalm G.B. Cyclosporine and tacrolimus: The mainstay of immunosuppressive therapy for solid organ transplantation. Clin Liver Dis 1997, 1:417-437.
10. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002, 34:47-54.
11. Ereshefsky L., Riesenman C., Lam Y.W. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995, 29(Suppl 1):10-18. discussion 18-19.
12. Ellingrod V.L., Perry P.J. Venlafaxine: A heterocyclic antidepressant. Am J Hosp Pharm 1994, 51:3033-3046.
13. Schweizer E., Thielen R.J., Frazer A. Venlafaxine: A novel antidepressant compound. Expert Opin Investig Drugs 1997, 6:65-78.
14. Wikell C., Hjorth S., Apelqvist G., et al. Sustained administration of the antidepressant venlafaxine in rats: Pharmacokinetic and pharmacodynamic findings. Naunyn Schmiedebergs Arch Pharmacol 2001, 363. 448-355.
15. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
16. Ueda K., Clark D.P., Chen C.J., et al. The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987, 262:505-508.
17. El Ela A.A., Hartter S., Schmitt U., et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004, 56:967-975.
18. Hitchins R.N., Harman D.H., Davey R.A., et al. Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur J Cancer Clin Oncol 1988, 24:449-454.
19. Tsuruo T., Iida H., Tsukagoshi S., et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-1972.
20. Weiss J., Dormann S.M., Martin-Facklam M., et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003, 305:197-204.
21. Ehret M.J., Levin G.M., Narasimhan M., et al. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 2007, 22:49-53.
22. Daoudaki M., Fouzas I., Stapf V., et al. Cyclosporine A augments P-glycoprotein expression in the regenerating rat liver. Biol Pharm Bull 2003, 26:303-307.
23. Takeguchi N., Ichimura K., Koike M., et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. Transplantation 1993, 55:646-650.
24. Hammann F., Gutmann H., Jecklin U., et al. Development of decision tree models for substrates, inhibitors, and inducers of P-glycoprotein. Curr Drug Metab 2009, 10:339-346.
25. Tyden E., Tallkvist J., Tjalve H., et al. P-glycoprotein in intestines, liver, kidney, and lymphocytes in horse. J Vet Pharmacol Ther 2009, 32:167-176.
26. PDR guide to drug interactions, side effects, and indications 2009, Thomson PDR, Montvale, NJ.
27. Uhr M., Grauer M.T., Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (MDR1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003, 54:840-846.
28. Thelen K., Dressman J.B. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009, 61:541-558.
29. Tachibana T., Kato M., Watanabe T., et al. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 2009, 39:430-443.
30. Summers M.A., Moore J.L., McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004, 38:1631-1634.
31. Perez-Tomas R. Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006, 13:1859-1876.
32. Sorrentino B.P. Gene therapy to protect hematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2002, 2:431-441.